Appetite Stimulation in Elderly Patients

Patient Selection and Clinical Context

• Elderly patients with appetite loss and concurrent depression should receive mirtazapine, as it addresses both conditions simultaneously and is well-tolerated with beneficial side effects including promotion of sleep, appetite, and weight gain, according to the American Academy of Family Physicians 1
• Patients with dementia without depression should not receive mirtazapine or any appetite stimulants, as the evidence shows no consistent benefit and potentially harmful side effects outweigh uncertain benefits for appetite and body weight, as stated by the Clinical Nutrition guidelines (89% consensus agreement) 2, 3, 4

Dosing and Administration

• The initial dose of mirtazapine for elderly patients should be 7.5 mg at bedtime, with a maximum dose of 30 mg at bedtime, and a full therapeutic trial requires at least 4-8 weeks to assess efficacy, as recommended by the American Academy of Family Physicians 1
• Mirtazapine is potent and well-tolerated, with sedating properties that make bedtime dosing ideal, according to the American Academy of Family Physicians 1

Expected Outcomes

• One small retrospective study in dementia patients showed mean weight gain of 1.9 kg at three months and 2.1 kg at six months, with approximately 80% experiencing some weight gain, although the evidence quality is weak due to the lack of placebo-controlled trials in elderly patients or those with dementia, as reported in Gastroenterology 2, 3, 4, 5
• The evidence for weight gain is limited but suggestive, with no placebo-controlled trials in elderly patients or those with dementia, making the evidence quality weak, as stated in Gastroenterology 2, 3, 4

Monitoring and Safety Considerations

• Regular reassessment is essential to evaluate benefit versus harm of pharmacological interventions, and after 9 months of treatment, consider dosage reduction to reassess the need for continued medication, as recommended by the American Academy of Family Physicians 1
• Discontinue mirtazapine over 10-14 days to limit withdrawal symptoms, according to the American Academy of Family Physicians 1

Appetite Stimulation in Elderly Patients

Assessment and Intervention

• The patient's poor appetite could be part of natural decline or due to treatable causes that should be investigated, according to the National Comprehensive Cancer Network 6
• Mirtazapine 7.5-15 mg at bedtime is recommended as a first-line pharmacological intervention to stimulate appetite in elderly patients, also addressing potential underlying depression, as suggested by the National Comprehensive Cancer Network 6, 7
• The American College of Physicians recommends considering alternative options such as megestrol acetate (400-800 mg/day) if mirtazapine is ineffective or contraindicated, with evidence for improved appetite 6, 8
• The National Comprehensive Cancer Network suggests that dexamethasone (2-8 mg/day) may be considered for shorter life expectancy, with a faster onset of action, but with caution due to significant side effects with prolonged use 7, 8

Non-Pharmacological Approaches

• Social interventions, such as encouraging shared meals with family or other patients, can improve intake, as recommended by the American Geriatrics Society 9, 10
• Dietary modifications, including offering smaller, more frequent meals with favorite foods and providing energy-dense options, can maximize nutritional intake, as suggested by the Academy of Nutrition and Dietetics 8
• Medication review is essential to identify potential contributors to poor appetite, such as iron supplements and multiple medications taken before meals, and consider temporarily discontinuing non-essential medications, as recommended by the American Society of Clinical Oncology 9, 7

Monitoring and Follow-up

• Regular reassessment is essential to evaluate benefit versus harm of pharmacological interventions, as suggested by the National Comprehensive Cancer Network 8
• If the patient is approaching end of life, focus on comfort and quality of life rather than nutritional goals, as recommended by the National Comprehensive Cancer Network 6, 7
• Avoid appetite stimulants if the patient has dementia with no evidence of depression, as suggested by the American Academy of Neurology 11, 10

Appetite Stimulation in Elderly Patients with Concurrent Conditions

Non-Pharmacological Interventions and Nutrition

• Consider fortified foods and oral nutritional supplements when dietary intake falls to 50-75% of usual intake, as these can increase energy and protein intake without requiring pharmacotherapy, according to the European Society for Clinical Nutrition and Metabolism 12, 13

Pharmacological Options

• The European Society for Clinical Nutrition and Metabolism recommends considering megestrol acetate 400-800 mg daily for appetite stimulation in elderly patients without depression, with a modest benefit-to-harm ratio, where approximately 1 in 4 patients will have increased appetite and 1 in 12 will gain weight 14
• The American Geriatrics Society suggests that evidence for mirtazapine is limited but suggestive, with one small retrospective study in dementia patients showing mean weight gain of 1.9 kg at 3 months and 2.1 kg at 6 months, with approximately 80% experiencing some weight gain 15, 16, 13
• The European Society for Clinical Nutrition and Metabolism states that megestrol acetate may attenuate benefits of resistance training, causing smaller gains or deterioration in muscle strength and functional performance, with critical safety concerns including thromboembolic events and adrenal suppression 12, 15, 13

Special Populations

• The European Society for Clinical Nutrition and Metabolism recommends avoiding appetite stimulants entirely in patients with dementia who do not have concurrent depression, as evidence for drugs as appetite stimulants in dementia is very limited and risks outweigh benefits 12, 15, 13
• The National Comprehensive Cancer Network suggests focusing on comfort and quality of life rather than nutritional goals for end-of-life patients, as overly aggressive nutritional interventions can increase suffering 14

Medications to Increase Appetite

First-Line Pharmacological Agent

• The Clinical Nutrition guidelines suggest that megestrol acetate may be associated with thromboembolic events, edema, and vaginal spotting, as well as higher rates of deaths compared to placebo 17
• Edema, impotence, and vaginal spotting are common side effects of megestrol acetate 17
• One Cochrane review found higher rates of deaths in the megestrol acetate group compared to placebo 17

Context-Specific Recommendations

• For patients with concurrent depression, mirtazapine 7.5-30 mg at bedtime may result in mean weight gain of 1.9 kg at 3 months and 2.1 kg at 6 months, with approximately 80% experiencing some weight gain 18
• For patients with dementia who do not have concurrent depression, appetite stimulants should not be used due to lack of consistent benefit and potential harmful side effects 18, 19
• The ESPEN guidelines suggest considering progestins to increase appetite in anorectic cancer patients with advanced disease 17
• Progestins increase appetite and body weight but not fat-free mass in cancer patients 17

Medications NOT Recommended

• Multiple guidelines conclude that evidence is insufficient to support routine use of cannabinoids for appetite stimulation 17
• Three small placebo-controlled trials in dementia patients found no significant effect of cannabinoids on body weight, BMI, or energy intake 18, 19

Appetite Stimulation in Elderly Patients with Concurrent Conditions

Initial Assessment and Context-Specific Selection

• The American Geriatrics Society recommends prioritizing non-pharmacological interventions before pharmacological appetite stimulants, and a medication review is essential to identify and temporarily discontinue non-essential medications that may contribute to poor appetite, such as iron supplements and multiple medications taken before meals 20
• Screening for malnutrition using validated tools such as NRS-2002, MNA, or MUST is crucial, and consideration of referral to nutritionist/dietician, dentist for poor dentition, or speech therapy for swallowing difficulties is recommended 20, 21

Monitoring and Reassessment

• Regular follow-up schedule to reassess at weeks 1, 2, 4, 8, and 12 to evaluate benefit versus harm is necessary, and after 9 months of mirtazapine treatment, consideration of dosage reduction to reassess need for continued medication is advised 20
• Discontinuation of mirtazapine over 10-14 days to limit withdrawal symptoms is recommended 20